≡ Menu

Allergan Biocell Textured Breast Implant Recall Issued Over Risk Of Breast Implant Associated Large Cell Lymphoma (BIA-ALCL)

Allergan Voluntarily Recalls Biocell Textured Breast Implants and Tissue Expanders Due To Potential Lymphoma Risk

On July 25, 2019, the U.S. Food and Drug Administration (FDA) announced that Allergan plc was issuing a worldwide recall of BIOCELL®textured breast implants and tissue expanders due to notification of global safety information from the FDA that showed an association between breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and Allergan BIOCELL® textured breast implants.

According to the FDA’s Allergan breast implant recall announcement, BIOCELL® saline-filled and silicone-filled textured breast implants and tissue expanders will no longer be distributed or sold.

The Allergan breast implants that were recalled include:

  • Natrelle Saline breast implant styles 168, 363, 468
  • Natrelle and McGhan 410 breast implant styles LL, LM, LF, LX, ML, MM, MF, MX, FL, FM, FF, FX
  • Natrelle and McGhan 410 Soft Touch breast implant styles LL, LM, LF, LX, ML, MM, MF, MX, FL, FM, FF, FX
  • Natrelle 510 Dual-Gel styles LX, MX, FX
  • Natrelle INSPIRA breast implants, styles TRL, TRLP, TRM, TRF, TRX, TSL, TSLP, TSM, TSF, TSX, TCL, TCLP, TCM, TCF, TCX
  • Natrelle and McGhan Round Gel Implants, styles 110, 110 Soft Touch, 120, 120 Soft Touch
  • Natrelle Komuro breast implants styles KML, KMM, KLL, and KLM
  • Natrelle Ritz Princess breast implant styles RML, RMM, RFL, RFM
  • Natrelle 150 Full Height and Short Height double lumen implants
  • Natrelle 133 tissue expanders with and without suture tabs: styles 133FV, 133MV, 133LV, 133MX, 133SX, 133SV, T-133FV,
    T-133MV, T-133LV, T-133MX, T-133SX, T-133SV, 133FV-T, 133MV-T, 133LV-T, 133MX-T, 133SX-T, 133SV-T
  • Natrelle 133 Plus tissue expander styles 133P-FV, 133P-MV, 133P-LV, 133P-MX, 133P-SX, 133P-SV, T-133P-FV, T-133P-MV, T-133P-LV, T-133P-MX, T-133P-SX, T-133P-SV, 133P-FV-T, 133P-MV-T, 133P-LV-T, 133P-MX-T, 133P-SX-T, 133P-SV-T

On June 1, 2020, the FDA announced that Allergan Aesthetics was initiating a digital campaign to improve breast implant and tissue expander device tracking and to identify and reach breast implant patients who have, or have had, BIOCELL® breast implants and/or tissue expanders to inform them of the risk of BIA-ALCL.

If you have Allergan textured breast implants that were the subject of the Allergan breast implant recall and were diagnosed with breast implant associated large cell lymphoma (BIA-ALCL), you may be able to seek compensation from an Allergan breast implant recall lawsuit.

If You Have Thoughts On The Allergan Recall, Share Your Comments Below.

{ 0 comments… add one }

Leave a Comment